FAQ

OncoRevive is a biotechnology company pioneering high-sensitivity liquid biopsy (blood test) platforms. We are dedicated to transforming cancer care through non-invasive blood tests that monitor treatment efficacy in real-time and advance the frontiers of early detection.

While the first generation of liquid biopsies has proven that "detecting cancer in blood" is possible, significant barriers remain in cost, accessibility, and the ability to find cancer at its absolute earliest stages as well as providing comprehensive multiomics information for doctors.

OncoRevive is closing these gaps through three key pillars of differentiation:

1. Superior Sensitivity in "Low-Shedding" Stages

Existing tests often struggle to detect Stage I or II cancers because the amount of circulating tumor DNA (ctDNA) is incredibly low. OncoRevive utilizes combination of nanotechnology, AI and analytical techniques that amplifies the signal-by 1 billion times-from even the smallest tumor fragments. This allows us to detect changes in cancer biomarkers.

2. Real-Time Treatment Monitoring (Dynamic vs. Static)

Many current technologies offer a "yes/no" answer to whether cancer is present and they provide information about only one category of biomarkers (e.g., mostly DNA only  or protein only). OncoRevive is designed for dynamic monitoring. Our platform tracks the shift in various biomarkers in the blood to tell doctors within 2 hours—not weeks—if a chemotherapy or immunotherapy is working, preventing patients from enduring weeks of ineffective, toxic treatments.

3. Radical Accessibility & Cost

The current market leaders often require high-end laboratory equipment and costs upwards of $4,000 per test. We are engineering our technology to be:

• Decentralized: Capable of being processed in local clinical labs rather than a single massive central facility.

• Affordable: Reducing the cost per test to make routine "cancer check-ups" a financial reality for healthcare systems globally.

OncoRevive has successfully transitioned from conceptual framework to Clinical Proof-of-Concept. We have moved beyond the laboratory bench and are now validating our platform using real-world data.

Our current progress is defined by two major pillars:

1. Proven Clinical Signal

We have successfully tested our technology on human cancer patient samples. These studies have demonstrated our platform’s ability to accurately identify biomarkers on circulating tumor cells and differentiate between samples from cancer patients and healthy donors. This data provides the foundational "signal" required to move toward larger-scale clinical utility.

2. Protected Intellectual Property (IP)

Our core technology is fully patented. We have secured our innovations in multiomics detection and isolation of cancer cells from blood stream, ensuring that OncoRevive holds a protected and competitive position in the liquid biopsy market as we scale.

OncoRevive is employing a "Lead-to-Platform" strategy. We are focusing our initial validation on high-impact indications where current monitoring and detection tools are most limited.

1. Lead Indication: Breast Cancer

Our primary focus is on breast cancer. This cancer often requires invasive biopsies or frequent, expensive imaging (CT/PET scans) to monitor progress. By proving our technology’s ability to detect early recurrence and therapy resistance in these patients, we can provide immediate clinical value and establish a regulatory foothold.

2. Strategic Expansion: Colorectal and Ovarian Cancers

Following our lead indication, we are expanding our validation to include Colorectal and Ovarian cancers. These are "high-utility" targets for liquid biopsy because:

• Colorectal: High demand for post-surgical monitoring (Minimal Residual Disease).

• Ovarian: Often "silent" until late stages; our high-sensitivity early detection could radically improve survival rates.

3. Long-term Vision: Multi-Cancer Early Detection (MCED)

While we are starting with specific solid tumors, the OncoRevive platform is designed to be cancer-agnostic. Our long-term goal is to integrate our patented technology into a universal screening tool capable of detecting dozens of cancer types from a single, routine annual blood draw.

As a pre-seed company, our primary focus has been on securing our Intellectual Property (IP) and achieving internal clinical proof-of-concept. While we do not have public manuscripts available at this exact moment, our data and technology are ready for expert review under specific conditions.

Our Path to Publication:

• Confidential Data Review: Because our core technology is now fully patented, we can share our internal validation data and "bench-to-patient" results with qualified partners and investors. This information can be disclosed following the execution of a Non-Disclosure Agreement (NDA).

• University Research Collaborations: A key pillar of our post-seed funding roadmap is to initiate formal collaborations with leading academic institutions. These partnerships will focus on the external independent validation of our platform using larger, diverse patient cohorts.

Yes. We believe that the most impactful diagnostic breakthroughs happen at the intersection of industry, academia, and clinical practice. We are actively seeking strategic partnerships to expand our validation data and refine our platform’s clinical utility.

We are specifically looking for partners in the following areas:

• Clinical Validation & Multi-Center Studies: We are eager to collaborate with oncology departments and research hospitals to conduct larger-scale retrospective and prospective studies. Our goal is to test our high-sensitivity blood test across broader patient demographics and cancer subtypes.

• Longitudinal Patient Tracking: We are seeking clinical partners interested in using our technology to track treatment response in real-time, helping to establish new protocols for "dynamic monitoring" in chemotherapy and immunotherapy.

• Biobank & Sample Access: To further sharpen our early-detection algorithms, we are looking for partnerships with academic biobanks that can provide de-identified, high-quality longitudinal samples.

• Co-Development of Lead Indications: We welcome inquiries from academic principal investigators (PIs) whose research aligns with our primary targets in cancer biomarker detection and monitoring.

We have already completed our initial Clinical Proof-of-Concept by successfully validating our technology on human cancer patient samples. This successful "pilot" phase has provided the data necessary to move into formal, large-scale clinical validation.

Our roadmap for clinical trials is divided into three strategic phases:

Phase 1: Expansion & Optimization

Following our upcoming seed funding, we will expand our testing to a larger cohort of retrospective samples. This phase focuses on "stress-testing" our patented technology across different cancer stages and subtypes to lock in the final version of our commercial assay.

Phase 2: Prospective Clinical Validation (Target: [Year, e.g., 2027])

We intend to launch our first Prospective Multi-Center Study in collaboration with our university and hospital partners. Unlike our previous work with stored samples, this trial will follow patients in real-time to demonstrate how OncoRevive can monitor cancer treatment.

Phase 3: Pivotal Trial for Regulatory Approval

The final step will be a pivotal study designed to support our submission for FDA clearance (via the De Novo or 510(k) pathway) and TGA certification. 

Follow us on LinkedIn is our primary hub for real-time announcements.

Direct Inquiries for Partners and Investors: 

 If you are looking for specific technical data or are interested in a strategic collaboration, we invite you to reach out directly.

• For Investment Inquiries: hello@oncorevive.com

• For Academic/Clinical Partnerships: partnership@oncorevive.com